Phaseline

Targets › FGFR4

FGFR4 (Fibroblast growth factor receptor 4): drug programs, companies and trials

16 programs from 15 companies in 64 trials: 40 Phase 2, 16 Phase 1, 8 Phase 3; Oncology, Gastroenterology, Other; next expected readout Nov 2026.

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid…. (UniProt, P22455)

Open in Phaseline: the race on FGFR4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TransThera Sciences (Nanjing)TT-00420 (tinengotinib)
Fibroblast growth factor receptor (FGFR) inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 3Cholangiocarcinoma; Cholangiocarcinoma Metastatic; Breast Cancer; Prostate Cancer (CRPC)Dec 2026
ExelixisZanzalintinib (XL092)
Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL
FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRAPhase 3Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma …Dec 2026
Johnson & Johnson (Janssen)Erdafitinib (TAR-210)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 3Urothelial Cancer; Non-Muscle Invasive Bladder Neoplasms; Urothelial Carcinoma; Advanced Malignant Solid Neoplasm …Dec 2026
Taiho OncologyFutibatinib (TAS-120)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2Advanced Cholangiocarcinoma; Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Advanced/Metastatic Cancer; Biliary Tract Neoplasms …Dec 2026
Shanghai Zhongshan HospitalHRS-4642
FGFR1/2/3/4 inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 2Biliary Tract Cancer; Pancreatic CancerDec 2026
National Cancer Institute (NCI)Rogaratinib
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2Locally Advanced Gastrointestinal Stromal TumorJul 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDonafenib
Multi-kinase inhibitor with activity against FGFRs, VEGFR, and RET
FGFR1, FGFR2, FGFR3, FGFR4Phase 2Hepatocellular CarcinomaJan 2028
National Cancer Center, JapanE7090
FGFR inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 2Advanced or Recurrent Solid TumorsMar 2028
Asan Medical CenterIrpagratinib
FGFR4 inhibitor
FGFR4Phase 2Carcinoma, HepatocellularMar 2029
QED Therapeutics, a BridgeBio companyInfigratinib
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2AchondroplasiaMar 2030
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestDerazantinib
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 2Intrahepatic Cholangiocarcinoma–
Biohaven TherapeuticsTaldefgrobep Alfa
FGF21 receptor agonist (FGF21 analog)
FGFR1, FGFR4, KLBPhase 2Obesity–
AstraZenecaFexagratinib (AZD4547)
Fibroblast growth factor receptor inhibitor
FGFR3, FGFR1, FGFR4, FGFR2Phase 1Muscle Invasive Bladder Cancer; Metastatic Breast CancerNov 2026
BroadenbioBB102
FGFR4 inhibitor
FGFR4Phase 1Advanced Solid TumorDec 2026
National Cancer Institute (NCI)FGFR4-CAR T Cells
FGFR4-targeting chimeric antigen receptor T cell therapy
FGFR4Phase 1RhabdomyosarcomaDec 2027
Tyra BiosciencesTYRA-430
FGFR inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 1Metastatic Hepatocellular CarcinomaJan 2028

Conditions

Non-Muscle Invasive Bladder Neoplasms (3) Colorectal Cancer (3) Hepatocellular Carcinoma (2) Urothelial Cancer (2) Advanced Malignant Solid Neoplasm (2) Advanced Solid Tumor (2) Muscle Invasive Bladder Cancer (1) Metastatic Breast Cancer (1) Urothelial Carcinoma (1) Advanced Lymphoma (1) Malignant Solid Neoplasm (1) Bladder Cancer (1)

Modalities

small molecule (10), mixed (5), antibody (1)

Companies

National Cancer Institute (NCI) (2) AstraZeneca (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Johnson & Johnson (Janssen) (1) Taiho Oncology (1) Shanghai Zhongshan Hospital (1) Exelixis (1) QED Therapeutics, a BridgeBio company (1) National Cancer Center, Japan (1) TransThera Sciences (Nanjing) (1) Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) Asan Medical Center (1) Broadenbio (1) Tyra Biosciences (1) Biohaven Therapeutics (1)

Related targets

FGFR1 (13) FGFR3 (12) FGFR2 (12) MET (1) KIT (1) PDGFRA (1) KLB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.